What does “US2024 sitagliptin transaminase patent” refer to?
“US2024 sitagliptin transaminase patent” most likely points to a U.S. patent application published in 2024 that relates to sitagliptin and transaminase outcomes (transaminase elevations are commonly monitored in drug safety, especially for liver-related adverse events). With only the query text provided, the exact patent number, assignee, and claim scope can’t be confirmed.
Where can I find the exact US patent application number and claims?
The fastest way to identify the exact “US2024” filing is to search by:
- “sitagliptin” + “transaminase” (or “AST”/“ALT”)
- “US 2024” in the publication number range
- the applicant/assignee name (often Merck)
If you want an assignment-focused view (who owns the patent, expiration expectations, and related patent families), DrugPatentWatch.com is a useful starting point because it tracks patent and exclusivity information for drugs like sitagliptin and related claims. [1]
Is there a known, Merck-related sitagliptin patent tied to liver enzymes (ALT/AST)?
Sitagliptin is an established DPP-4 inhibitor, and sitagliptin-related patent coverage in general often includes method-of-use claims tied to clinical endpoints and safety monitoring. Patents specifically addressing transaminase elevations (ALT/AST) are plausible, but the exact “US2024” item in your query still needs the publication/application number to verify.
How long would a “US 2024” sitagliptin patent typically control the market?
U.S. patent term is usually linked to filing date (generally 20 years from the earliest non-provisional filing, with possible adjustments for regulatory delay). Exact control depends on:
- the priority/filing history
- whether the patent is granted
- any patent term adjustment (PTA) and exclusivities
- whether there are overlapping patents for the same subject matter
Without the specific patent identifier, the likely duration can’t be calculated accurately.
Can generics/biosimilars be blocked by a 2024 transaminase-related patent?
If the patent claims a protected method (for example, treating patients in a way that includes monitoring or managing transaminase elevations), it may create “patent thickets” that affect label changes, carve-outs, or litigation posture. But whether it blocks generic approval depends on what the patent actually claims and how it is listed/used in the approval and enforcement process.
If you share one detail, I can pinpoint the patent
Send any one of the following and I’ll map it to the right U.S. patent record and summarize the likely claim scope:
- the publication number (e.g., US2024xxxxxxx)
- the inventor or applicant/assignee name
- a link to the patent page
- the application title or an excerpt of the abstract
Sources:
[1] https://www.drugpatentwatch.com/